Verrica Pharmaceuticals Inc. Retained Earnings
Verrica Pharmaceuticals Inc. (VRCA) had Retained Earnings of -$347.75 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$347.75M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$334.60M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$324.91M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$316.84M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$347.75M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$334.60M 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$324.91M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$316.84M 10-Q · filed 2025-11-14 |
| 2025-06-30 | -$316.56M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$316.77M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$307.03M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$290.82M 10-Q · filed 2024-11-05 |
| 2024-06-30 | -$267.96M 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$250.78M 10-Q · filed 2024-05-13 |
| 2023-12-31 | -$230.45M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$205.83M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$181.03M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$170.04M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$163.45M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$157.52M 10-Q · filed 2022-11-07 |
| 2022-06-30 | -$157.60M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$147.44M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$138.97M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$129.43M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$116.60M 10-Q · filed 2021-08-10 |
| 2021-03-31 | -$104.82M 10-Q · filed 2021-05-07 |
| 2020-12-31 | -$103.89M 10-K · filed 2022-03-02 |
| 2020-09-30 | -$90.91M 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$80.42M 10-Q · filed 2020-08-05 |
| 2020-03-31 | -$71.01M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$61.19M 10-K · filed 2021-03-17 |
| 2019-09-30 | -$53.55M 10-Q · filed 2019-11-06 |
| 2019-06-30 | -$47.47M 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$40.46M 10-Q · filed 2019-05-07 |
| 2018-12-31 | -$33.08M 10-K · filed 2020-03-13 |
| 2018-09-30 | -$27.01M 10-Q · filed 2018-11-07 |
| 2018-06-30 | -$20.27M 10-Q · filed 2018-08-07 |
| 2017-12-31 | -$12.44M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |